Quantum BioPharma Ltd. (FSDDF) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Quantum BioPharma Ltd. (NASDAQ:QNTM) is a Canadian biopharmaceutical company headquartered in Toronto that focuses on developing treatments for challenging neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders. Originally founded as FSD Pharma Inc., the company rebranded to Quantum BioPharma Ltd. in August 2024 to better reflect its strategic focus on biopharmaceutical development. The company operates as a clinical-stage biotech firm with drug candidates in various stages of development, maintaining a dual business model that combines pharmaceutical research with strategic real estate investments.

Ask drillr about Quantum BioPharma Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−24.89M

Op. CF (TTM)

−5.42M

Latest newsMore news →

Quantum BioPharma signed a contract with Thermo Fisher Scientific's clinical research business to implement the Phase 2 Lucid-MS trial of its neuroprotective therapy in multiple sclerosis.30d ago

Unbuzzd Wellness, a licensee of Quantum BioPharma, appointed Zappy as its CEO.41d ago

Latest newsMore news →

Quantum BioPharma signed a contract with Thermo Fisher Scientific's clinical research business to implement the Phase 2 Lucid-MS trial of its neuroprotective therapy in multiple sclerosis.30d ago Unbuzzd Wellness, a licensee of Quantum BioPharma, appointed Zappy as its CEO.41d ago Quantum BioPharma Ltd. received FDA clearance to begin clinical trials for a multiple sclerosis treatment.56d ago